Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer

Wednesday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM). The approval marks the first indication for Keytruda in MPM in the U.S. Also Read: Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study. MPM is a rare, aggressive cancer that forms in the lining of the lungs and chest. The approval is based on pivotal Phase 2/3 IND.227/KEYNOTE-483 ...